Florian Stehling
Overview
Explore the profile of Florian Stehling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
487
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kavvalou A, Stehling F, Goretzki S, Dohna-Schwake C, Rath P, Steindor M
Infect Dis (Lond)
. 2023 Nov;
56(3):255-258.
PMID: 38015560
are a large order of ubiquitous saprophytic zygomycete fungi and act as opportunistic pathogens in humans. In pediatric patients, little is known about the role of in airway colonization and...
12.
Gruber W, Welsner M, Blosch C, Dillenhoefer S, Olivier M, Brinkmann F, et al.
Healthcare (Basel)
. 2023 Nov;
11(21).
PMID: 37958017
Background: Longitudinal data on changes in health-related quality of life (HRQoL) in adult people with cystic fibrosis (pwCF) and the longitudinal effects of Elexacaftor/Tezacaftor/Ivacaftor therapy (ETI) on HRQoL or HRQoL...
13.
Schafer H, Barker M, Follmann P, Gunther A, Horning A, Kaiser-Labusch P, et al.
Eur J Pediatr
. 2023 Sep;
182(11):5167-5179.
PMID: 37707590
Conclusions: Close contact to MDR cases or birth in MDR-TB-high-incidence countries are risk factors for MDR-pTB. Early identification of potential MDR index cases by contact investigation, and susceptibility testing in...
14.
Sutharsan S, Dillenhoefer S, Welsner M, Stehling F, Brinkmann F, Burkhart M, et al.
Lancet Reg Health Eur
. 2023 Aug;
32:100690.
PMID: 37554663
Background: Treatment with elexacaftor/tezacaftor/ivacaftor (ETI) improves multiple clinical outcomes in people with cystic fibrosis (pwCF) with at least one F508del allele. This study evaluated the real-world impact of ETI on...
15.
Gilchrist F, Bui S, Gartner S, McColley S, Tiddens H, Ruiz G, et al.
J Cyst Fibros
. 2023 Jul;
23(1):80-86.
PMID: 37455237
Background: Antibiotic eradication therapies recommended for newly isolated Pseudomonas aeruginosa (Pa) in people with cystic fibrosis (pwCF) can be burdensome. ALPINE2 compared the efficacy and safety of a shortened 14-day...
16.
Niehammer U, Strassburg S, Sutharsan S, Taube C, Welsner M, Stehling F, et al.
BMC Pulm Med
. 2023 Jun;
23(1):190.
PMID: 37264349
Background: The present study evaluates personality traits in adult patients with cystic fibrosis (CF) and correlates these results with health-related quality of life (HRQoL) and other clinical parameters indicative of...
17.
Olivier M, Kavvalou A, Welsner M, Hirtz R, Strassburg S, Sutharsan S, et al.
Front Pharmacol
. 2023 May;
14:1176815.
PMID: 37229253
Recently, cystic fibrosis transmembrane regulator modulator therapy with elexacaftor/tezacaftor/ivacaftor has become available for children with cystic fibrosis (CF) carrying at least one mutation. To assess the intermediate term effects of...
18.
Boschen E, Wendt A, Muller-Stover S, Piechnik L, Fuchs H, Lund M, et al.
Eur J Pediatr
. 2023 Apr;
182(7):2999-3006.
PMID: 37121990
The number of children with tracheostomies with and without home mechanical ventilation has grown continuously in recent years. For some of these children, the need for tracheostomy resolves and the...
19.
Ring A, Schwerk N, Kiper N, Tana Aslan A, Aurora P, Ayats R, et al.
ERJ Open Res
. 2023 Apr;
9(2).
PMID: 37101741
Background: Paediatric diffuse alveolar haemorrhage (DAH) is a rare heterogeneous condition with limited knowledge on clinical presentation, treatment and outcome. Methods: A retrospective, descriptive multicentre follow-up study initiated from the...
20.
Goralski J, Hoppe J, Mall M, McColley S, McKone E, Ramsey B, et al.
Am J Respir Crit Care Med
. 2023 Mar;
208(1):59-67.
PMID: 36921081
Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) has been shown to be safe and effective in people with cystic fibrosis (CF) aged ⩾6 years with at least one allele but has not been studied in...